Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Capital Leases (2024 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Capital Leases for 2 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • Quarterly Capital Leases rose 29.56% to $4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Dec 2025, up 29.56% year-over-year, with the annual reading at $4.1 million for FY2025, 29.56% up from the prior year.
  • Capital Leases hit $4.1 million in Q4 2025 for Vanda Pharmaceuticals, up from $2.8 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $4.1 million in Q4 2025 to a low of $2.8 million in Q3 2025.